Helicobacter pylori (Hp) is a gram-negative bacterium which colonizes the stomach and duodenum, and can cause diseases such as gastritis, peptic ulcers and stomach cancer. Gastric cancer associated with Hp is one of the most common human malignancies, the fourth leading cause of cancer-related death worldwide, and a serious threat to human health, so the eradication of Hp is particularly important. However, with the abuse of antibiotics, the drug resistance of the bacteria has also been greatly improved, and the previous research schemes have gradually revealed drawbacks, while Chinese medicine treatment has unique advantages such as low recurrence rate, few side effects, and not easy to produce drug resistance. It is of great significance to make full use of the advantages of traditional Chinese medicine and continuously study new treatment plans for the eradication of Hp. This article mainly reviews the pathological mechanism, treatment progress and traditional Chinese medicine treatment of Hp.

1.Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection[J]. Nat Revi Dis Primers, 2023, 9(1): 19. https://doi.org/10.1038/s41572-023-00431-8.

2.Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic resistance and genotypic study of the Vac A, Cag A, Ice A, Oip A and Bab A genotypes of the Helicobacter pylori strains isolated from raw milk[J]. Antimicrob Resist Infect Control, 2018, 7(1): 115. DOI: 10.1186/s13756-018-0409-y.

3.Li YL, Li XY, Tan ZJ. An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis[J]. Helicobacter, 2021, 26(3): e12799. DOI: 10.1111/hel.12799.

4.Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection[J]. Helicobacter, 2017, 22: e12403. DOI: 10.1111/hel.12403.

5.Pucułek M, Machlowska J, Wierzbicki R, et al. Helicobacter pylori associated factors in the development of gastric cancer with special reference to the early-onset subtype[J]. Oncotarget, 2018, 9(57): 31146-31162. DOI: 10.18632/oncotarget.25757.

6.Ren S, Cai PP, Liu YQ, et al. Prevalence of Helicobacter pylori infection in China: a systematic review and meta‐analysis[J]. J Gastroenterol Hepatol, 2022, 37(3): 464-470. DOI: 10.1111/jgh.15751.

7.Maubach G, Vieth M, Boccellato F, et al. Helicobacter pylori-induced NF-κB: trailblazer for gastric pathophysiology[J]. Trends Mol Med, 2022, 28(3): 210-222. DOI: 10.1016/j.molmed.2021.12.005.

8.Sokolova O, Naumann M. Matrix metalloproteinases in Helicobacter pylori-associated gastritis and gastric cancer[J]. Int J Mol Sci, 2022, 23(3): 1883. DOI: 10.3390/ijms23031883.

9.Toyoshima O, Nishizawa T, Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis[J]. World J Gastroenterol, 2020, 26(5): 466-477.DOI: 10.3748/wjg.v26.i5.466.

10.Gao PP, Cai N, Yang XR, et al. Association of Helicobacter pylori and gastric atrophy with adenocarcinoma of the esophagogastric junction in Taixing, China[J]. Int J Cancer, 2022, 150(2): 243-252. DOI: 10.1002/ijc.33801.

11.陈署洪, 吕冠华. 中西医治疗幽门螺杆菌感染研究进展[J]. 中外医学研究, 2023, 21(5): 175-180. [Chen SH, Lyu GH. Research progress on treatment of Helicobacter pylori infection with Chinese and Western medicine[J]. Chinese and Foreign Medical Research, 2023, 21(5): 175-180.] DOI: 10.14033/j.cnki.cfmr.2023.05.044.

12.李珂, 吕冠华. 幽门螺杆菌耐药的中医药研究进展[J]. 中国民间疗法, 2019, 27(21): 103-105. DOI: 10.19621/j.cnki.11-3555/r.2019.2154.

13.王敏, 盛小燕, Ackroyd SC, 等. 幽门螺杆菌致病机制和治疗方法的研究进展[J]. 胃肠病学, 2021, 26(9): 569-573. [Wang M, Sheng XY, Ackroyd SC, et al. Research progress in pathogenesis and treatment of Helicobacter pylori[J]. Chinese Journal of Gastroenterology, 2021, 26(9): 569-573.] DOI: 10.3969/j.issn.1008-7125.2021.09.009.

14.吴林苗, 江剑平. 幽门螺杆菌致病机制及其治疗方式研究进展[J]. 保健医学研究与实践, 2021, 18(4): 144-148. [Wu LM, Jiang JP. Research progress on pathogenic mechanism and treatment of Helicobacter pylori[J]. Health Medicine Research and Practice, 2021, 18(4): 144-148.] DOI: 10.11986/j.issn.1673-873X.2021.04.031.

15.黄览, 王道敏, 黄赞松, 等. 幽门螺杆菌定植与致病机制的研究新进展[J]. 中国医学创新, 2022, 19(14): 166-170. [Huang L, Wang DM, Huang ZS, et al. New progress in the study of colonization and pathogenic mechanism of Helicobacter pylori[J]. Medical Innovation of China, 2022, 19(14): 166-170.] DOI: 10.3969/j.issn.1674-4985. 2022.14.041.

16.罗微, 王倩, 陈铁龙. 幽门螺杆菌鞭毛研究概述[J]. 中国病原生物学杂志, 2015, 10(9): 852-857. [Luo W, Wang Q, Chen TL. Overview of research on Helicobacter pylori flagella[J]. Journal of Pathogen Biology, 2015, 10(9): 852-857.] DOI: 10.13350/j.cjpb.150922.

17.Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms[J]. Braz J Microbiol, 2022, 53(1): 33-50. DOI: 10.1007/s42770-021-00675-0.

18.Suzuki S, Kusano C, Horii T, et al. The ideal Helicobacter pylori treatment for the present and the future[J]. Digestion, 2022, 103(1): 62-68. DOI: 10.1159/000519413.

19.Suzuki S, Esaki M, Kusano C, et al. Development of Helicobacter pylori treatment: how do we manage antimicrobial resistance?[J]. World J Gastroenterol, 2019, 25(16): 1907-1912. DOI: 10.3748/wjg.v25.i16.1907

20.Liu LG, Nahata MC. Vonoprazan with amoxicillin or amoxicillin and clarithromycin for the treatment of Helicobacter pylori infection[J]. Ann Pharmacothe, 2023, 57(10): 1185-1197. DOI: 10.1177/10600280221149708.

21.Moghadam MT, Chegini Z, Khoshbayan A, et al. Helicobacter pylori biofilm and new strategies to combat it[J]. Curr Mol Med, 2021, 21(7): 54-561. DOI: 10.2174/1566524020666201203165649.

22.Chen X, Li P, Shen Y, et al. Rhamnolipid-involved antibiotics combinations improve the eradication of Helicobacter pylori biofilm in vitro: a comparison with conventional triple therapy[J]. Microb Pathog, 2019, 131: 112-119. DOI: 10.1016/j.micpath.2019.04.001.

23.Hu Q, Peng Z, Li LL, et al. The Efficacy of berberine-containing quadruple therapy on Helicobacter Pylori eradication in China: a systematic review and Meta-analysis of randomized clinical trials[J]. Front Pharmacol, 2020, 10: 1694. DOI: 10.3389/fphar.2019.01694. eCollection 2019.

24.刘芳勋, 张晶, 张华, 等. 铋剂在幽门螺杆菌根除中的不良反应及预防[J]. 临床药物治疗杂志, 2014, 12(5): 59-62. [Liu FX, Zhang J, Zhang H, et al. Adverse reactions and prevention of bismuth agent in eradication of Helicobacter pylori[J]. Clinical Medication Journal, 2014, 12(5): 59-62.] DOI: 10.3969/j.issn.1672-3384.2014.05.013.

25.Kim SK, Guevarra RB, Kim YT, et al. Role of probiotics in human gut microbiome-associated diseases[J]. J Microbiol Biotechnol, 2019, 29(9): 1335-1340. DOI: 10.4014/jmb.1906.06064.

26.Chen LY, Xu WL, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial[J]. EBioMedicine, 2018, 35: 87-96. DOI: 10.1016/j.ebiom.2018.08.028.

27.Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections[J]. Adv Exp Med Biol, 2019, 1149: 211-225. DOI: 10.1007/5584_ 2019_367.

28.Nabavi-Rad A, Sadeghi A, Aghdaei HA, et al. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management[J]. Gut Microbes, 2022, 14(1): 2108655. DOI: 10.1080/19490976.2022.2108655.

29.Shi XG, Zhang JH, Mo LS, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis[J]. Medicine (Baltimore), 2019, 98(15): e15180. DOI: 10.1097/MD.0000000000015180.

30.Zanotti G, Cendron L. Structural aspects of Helicobacter pylori antibiotic resistance[J]. Adv Exp Med Biol, 2019, 1149: 227-241. DOI: 10.1007/5584_2019_368.

31.Tseng YS, Wu DC, Chang CY, et al. Amoxicillin resistance with β-lactamase production in Helicobacter pylori[J]. Eur J Clin Invest, 2009, 39(9): 807-812. DOI: 10.1111/j.1365-2362.2009.02166.x.

32.Alarcón-Millán J, Bonilla-Delgado J, Fernández-Tilapa G, et al. Helicobacter pylori virulence factors and clarithromycin resistance-associated mutations in mexican patients[J]. Pathogens, 2023, 12(2): 234. DOI: 10.3390/pathogens12020234.

33.Gong YH, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy[J]. Crit Rev Microbiol, 2018, 44(3): 371-392. DOI: 10.1080/1040841X.2017.1418285.

34.Zagari RM, Dajti E, Cominardi A, et al. Standard bismuth quadruple therapy versus concomitant therapy for the first-line treatment of Helicobacter pylori infection: a systematic review and Meta-analysis of randomized controlled trials[J]. J Clin Med, 2023, 12(9): 3258. DOI: 10.3390/jcm12093258.

35.Hu JN, He T, Liu JF, et al. Pharmacological and molecular analysis of the effects of Huangqi Jianzhong decoction on proliferation and apoptosis in GES-1 cells infected with H. pylori[J]. Front Pharmacol, 2022, 13: 1009705. DOI: 10.3389/fphar.2022.1009705.

36.Sun Y, Zhang J. Helicobacter pylori recrudescence and its influencing factors[J]. J Cell Mol Med, 2019, 23(12): 7919-7925. DOI: 10.1111/jcmm.14682.

37.Xu WC, Li BL, Xu MC, et al. Traditional Chinese medicine for precancerous lesions of gastric cancer: a review[J]. Biomed Pharmacother, 2022, 146: 112542. DOI: 10.1016/j.biopha.2021.112542.

38.Li RJ, Dai YY, Qin C, et al. Application of traditional Chinese medicine in treatment of Helicobacter pylori infection[J]. World J Clin Cases, 2021, 9(35): 10781-10791. DOI: 10.12998/wjcc.v9.i35.10781.

39.鲁强, 马润芳, 谢建辉, 等. 中药治疗幽门螺杆菌相关性胃炎的系统评价[J]. 时珍国医国药, 2021, 32(2): 481-486. [Lu Q, Ma RF, Xie JH, et al. Systematic evaluation of traditional Chinese medicine in the treatment of Helicobacter pylori associated gastritis[J]. Lishizhen Medicine and Materia Medica Research, 2021, 32(2): 481-486.] DOI: 10.3969/j.issn.1008-0805.2021.02.69.

40.Yu Z, Sheng WD, Yin X, et al. Coptis, Pinellia, and Scutellaria as a promising new drug combination for treatment of Helicobacter pylori infection[J]. World J Clin Cases, 2022, 10(34): 12500-12514. DOI: 10.12998/wjcc.v10.i34.12500.

41.耿聪, 李岩, 姚鑫洁. 三黄泻心汤三味药联合抗生素对幽门螺杆菌的体外抑菌实验研究[J]. 实用药物与临床, 2021, 24(4): 307-311. [Geng C, Li Y, Yao XJ. Experimental study on antibacterial effect of Sanhuang Xiexin decoction combined with antibiotics on Helicobacter pylori in vitro[J]. Practical Pharmacy and Clinical Remedies, 2021, 24(4): 307-311.] DOI: 10.14053/j.cnki.ppcr.202104004.

42.Liu QS, Tang JY, Chen SL, et al. Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa's cascade underlie its therapeutic effects[J]. Pharmacol Res, 2022, 184: 106440. DOI: 10.1016/j.phrs.2022.106440.

43.Li CL, Huang P, Wong K, et al. Coptisine-induced inhibition of Helicobacter pylori: elucidation of specific mechanisms by probing urease active site and its maturation process[J]. J Enzyme Inhib Med Chem, 2018, 33(1): 1362-1375. DOI: 10.1080/14756366.2018.1501044.

44.Zhou JT, Li CL, Tan LH, et al. Inhibition of Helicobacter pylori and its associated urease by palmatine: investigation on the potential mechanism[J]. PLoS One, 2017, 12(1): e0168944. DOI: 10.1371/journal.pone.0168944.

45.Jung J, Choi JS, Jeong CS. Inhibitory activities of palmatine from coptis chinensis against Helicobactor pylori and gastric damage[J]. Toxicol Res, 2014, 30(1): 45-48. DOI: 10.5487/TR.2014.30.1.045.

46.周帆. 黄连素在幽门螺杆菌多重耐药与外排泵基因调控中的作用研究[D]. 上海: 上海中医药大学, 2021. DOI: 10.27320/d.cnki.gszyu.2019.000246.

47.Yu XD, Zheng RB, Xie JH, et al. Biological evaluation and molecular docking of baicalin and scutellarin as Helicobacter pylori urease inhibitors[J]. J Ethnopharmacol, 2015, 162: 69-78. DOI: 10.1016/j.jep.2014.12.041.

48.黄衍强, 黄干荣, 李晓华, 等. 中药提取物对耐药幽门螺杆菌生物膜形成的影响[J]. 医药导报, 2013, 32(11): 1407-1409. [Huang YQ, Huang GR, Li XH, et al. Effect of Chinese herbal extracts on biofilm formation of drug-resistant Helicobacter pylori[J]. Herald of Medicine, 2013, 32(11): 1407-1409.] DOI: 10.3870/yydb.2013.11.004.

49.Shen X, Zhang WJ, Peng C, et al. In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection[J]. Chin Med, 2021, 16(1): 33. DOI: 10.1186/s13020-021-00442-1.

50.王倩. 苍术化学成分药理作用研究进展[J]. 生物化工, 2023, 9(1): 158-162. [Wang Q. Research progress on pharmacological effects of chemical components of atractylodes lancea[J]. Biological Chemical Engineering, 2023, 9(1): 158-162.] DOI: 10.3969/j.issn.2096-0387. 2023.01.038.

51.Li L, Du YY, Wang Y, et al. Atractylone alleviates ethanol-induced gastric ulcer in rat with altered gut microbiota and metabolites[J]. J Inflamm Res, 2022, 15: 4709-4723. DOI: 10.2147/JIR.S372389.

52.Yu M, Wang XC, Ling F, et al. Atractylodes lancea volatile oils attenuated Helicobacter pylori NCTC11637 growth and biofilm[J]. Microb Pathog, 2019, 135: 103641. DOI: 10.1016/j.micpath.2019.103641.

53.Chang CH, Wu JB, Yang JS, et al. The suppressive effects of geniposide and genipin on Helicobacter pylori infections in vitro and in vivo[J]. J Food Sci, 2017, 82(12): 3021-3028. DOI: 10.1111/1750-3841.13955.

54.Lian DW, Xu YF, Deng QH, et al. Effect of patchouli alcohol on macrophage mediated Helicobacter pylori digestion based on intracellular urease inhibition[J]. Phytomedicine, 2019, 65: 153097. DOI: 10.1016/j.phymed.2019.153097.

55.Lian DW, Xu YF, Ren WK, et al. Unraveling the novel protective effect of patchouli alcohol against Helicobacter pylori-induced gastritis: insights into the molecular mechanism in vitro and in vivo[J]. Front Pharmacol, 2018, 9: 1347. DOI: 10.3389/fphar.2018.01347.

56.Xie JH, Lin ZX, Xian YF, et al. (−)-Patchouli alcohol protects against Helicobacter pylori urease-induced apoptosis, oxidative stress and inflammatory response in human gastric epithelial cells[J]. Int Immunopharmacol, 2016, 35: 43-52. DOI: 10.1016/j.intimp.2016.02.022.

57.伍世颖, 庄惠玲, 丁彧, 等. 广藿香醇抗幽门螺杆菌的作用及对肠道微生物的影响[J]. 中药新药与临床药理, 2019, 30(8): 927-934. [Wu SY, Zhuang HL, Ding  Y, et al. Anti-Helicobacter pylori effect and its influence on intestinal microorganisms[J]. Traditional Chinese Drug Research and Clinical Pharmacology, 2019, 30(8): 927-934.] DOI: 10.19378/j.issn.1003-9783.2019.08.007.

58.邓志燕,万强. 黄芩苷对幽门螺杆菌诱导人胃黏膜上皮GES-1细胞损伤的保护作用及机制[J]. 中国实验方剂学杂志, 2017, 23(19): 145-149. [Deng ZY, Wan Q. Protective effect and mechanism of baicalin on human gastric mucosal epithelial GES-1 cell injury induced by Helicobacter pylori[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2017, 23(19): 145-149.] DOI: 10.13422/j.cnki.syfjx.2017190145.

59.赵梁, 谭达全, 尹抗抗, 等. 半夏泻心汤对幽门螺杆菌毒力因子影响的实验研究[J]. 湖南中医杂志, 2014, 30(3): 114–116. [Zhao L, Tan DQ, Yin KK, et al. Experimental study on effect of Banxia Xiexin decoction on virulence factors of Helicobacter pylori[J]. Hunan Journal of Traditional Chinese Medicine, 2014, 30(3): 114-116.] DOI: 10.16808/j.cnki.issn1003-7705.2014.03.067.

60.Cao Y, Zheng Y, Niu J, et al. Efficacy of Banxia Xiexin decoction for chronic atrophic gastritis: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(10): e0241202. DOI: 10.1371/journal.pone.0241202.

61.Ji Q, Yang Y, Song XL, et al. Banxia Xiexin decoction in the treatment of chronic atrophic gastritis: a protocol for systematic review and Meta-analysis[J]. Medicine, 2020, 99(42): e22110. DOI: 10.1097/MD.0000000000022110.

62.陈月. 半夏泻心汤治疗慢性胃炎伴幽门螺杆菌阳性临床观察[J]. 中国中医药现代远程教育, 2023, 21(7): 99-101. [Chen Y. Clinical observation of Banxia Xiexin decoction in treating chronic gastritis with Helicobacter pylori[J]. Chinese Medicine Modern Distance Education of China, 2023, 21(7): 99-101.] DOI: 10.3969/j.issn.1672-2779.2023.07.034.

63.Chen YH, Lin Y, Shan CF, et al. Effect of Fufang Huangqi decoction on the gut microbiota in patients with class i or ii myasthenia gravis[J]. Front Neurol, 2022, 13: 785040. DOI: 10.3389/fneur.2022.785040.

64.Wu ZX, Pan XY, Deng CS, et al. Mechanism of herb pairs astragalus mongholicus and curcuma phaeocaulis valeton in treating gastric carcinoma: a network pharmacology combines with differential analysis and molecular docking[J]. Evid Based Complement Alternat Med , 2022, 2022: 8361431. DOI: 10.1155/2022/8361431.

65.Luo YT, Wu J, Zhu FY, et al. Gancao Xiexin decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and metabolites[J]. Drug Des Devel Ther, 2022,  16: 1383-1405. DOI: 10.2147/DDDT.S352467.

66.Wang RL, Wang YL, Lu Z, et al. Efficacy and safety of Zuojin pill for the treatment of chronic nonatrophic gastritis: a randomized active-controlled clinical trial[J]. Evid Based Complement Alternat Med, 2022, 2022: 2266023. DOI: 10.1155/2022/2266023.

67.Wen JX, Wu SH, Ma X, et al. Zuojin pill attenuates Helicobacter pylori-induced chronic atrophic gastritis in rats and improves gastric epithelial cells function in GES-1 cells[J]. J Ethnopharmacol, 2022, 285: 114855. DOI: 10.1016/j.jep.2021.114855.

68.王立明, 应春晓, 朱雅碧, 等. 荆花胃康胶丸联合三联疗法治疗Hp阳性慢性胃炎临床研究[J]. 新中医, 2023, 55(6): 46-49. [Wang LM, Ying CX, Zhu BY, et al. Clinical study of Jinghua Weikang capsule combined with triple therapy on Hp positive chronic gastritis[J]. Journal of New Chinese Medicine, 2023, 55(6): 46-49.] DOI: 10.13457/j.cnki.jncm.2023.06.010.

69.米彩锋, 赵武斌, 余儒桓, 等. 四联用药联合荆花胃康胶丸治疗Hp感染胃溃疡临床观察[J]. 光明中医, 2022, 37(14): 2612–2614. [Mi CF, Zhao WB, Yu RH, et al. Clinical observation of quadruple therapy combined with Jinghua Weikang capsule in the treatment of Hp infected gastric ulcer[J]. Guangming Journal of Chinese Medicine, 2022, 37(14): 2612-2614.] DOI: 10.3969/j.issn.1003-8914.2022.14.047.

70.Jia X, Huang Q, Lin M, et al. Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori[J]. Front Microbiol, 2022, 13: 962354. DOI: 10.3389/fmicb.2022.962354.

71.Zhao Q, Wang WJ, Zhou SP, et al. Jinghua Weikang capsule for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis[J]. Front Pharmacol, 2022, 13: 959184. DOI: 10.3389/fphar.2022.959184.

72.王增增, 李青. 甘草泻心汤加减治疗幽门螺杆菌相关性胃溃疡临床观察[J]. 实用中医药杂志, 2022, 38(8): 1305-1307. [Wang ZZ, Li Q. Clinical observation of Gancao Xiexin decoction in treatment of Helicobacter pylori associated gastric ulcer[J]. Journal of Practical Traditional Chinese Medicine, 2022, 38(8): 1305-1307.] https://www.cnki.com.cn/Article/CJFDTotal-ZYAO202208015.htm.

73.徐秀鹏. 甘草泻心汤治疗幽门螺杆菌相关性胃溃疡的临床研究[D]. 济南: 山东中医药大学, 2014. https://cdmd.cnki.com.cn/Article/CDMD-10441-1015511834.htm.

74.Luo YT, Wu J, Zhu FY, et al. Gancao Xiexin decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and metabolites[J]. Drug Des Devel Ther, 2022, 16: 1383-1405. DOI: 10.2147/DDDT.S352467.

75.Chen X, Hu LJ, Wu HH, et al. Anti- Helicobacter pylori and anti-inflammatory effects and constituent analysis of modified Xiaochaihutang for the treatment of chronic gastritis and gastric ulcer[J]. Evid Based Complement Alternat Med, 2018, 2018: 6810369. DOI: 10.1155/2018/6810369.

76.黄晓雪, 张霖. 中医药治疗幽门螺杆菌感染的研究进展[J]. 中国处方药, 2022, 20(11): 177-179. DOI: 10.3969/j.issn.1671-945X.2022.11.064.

77.Zhong MF, Li J, Liu XL, et al. TCM-based therapy as a rescue therapy for re-eradication of Helicobacter pylori infection: a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med , 2022, 2022: 5626235. DOI: 10.1155/2022/5626235.

78.Xie C, Liu LH, Zhu SY, et al. Effectiveness and safety of Chinese medicine combined with omeprazole in the treatment of gastric ulcer: a protocol for systematic review and meta-analysis[J]. Medicine, 2021, 100(17): e25744. DOI: 10.1097/MD.0000000000025744.

79.Wei Y, Ma LX, Yin SJ, et al. Huangqi Jianzhong Tang for treatment of chronic gastritis: a systematic review of randomized clinical trials[J]. Evid Based Complement Alternat Med , 2015, 2015: 878164. DOI: 10.1155/2015/ 878164.

80.季科, 薛育政, 吴铁龙, 等. 铋剂四联法联合柴胡疏肝散治疗胃溃疡的效果分析[J]. 湖南师范大学学报(医学版), 2021, 18(6): 55-58. [Ji K, Xue YZ, Wu TL, et al. Effect analysis of bismuth quadruple combined with Bupleurum Shugan powder in the treatment of gastric ulcer[J]. Journal of Hunan Normal University (Medical Sciences), 2021, 18(6): 55-58.] DOI: 10.3969/j.issn.1673-016X.2021.06.017.

81.徐清锋, 曾剑山. 半夏泻心汤联合抗Hp四联疗法治疗寒邪客胃型萎缩性胃炎45例[J]. 光明中医, 2023, 38(5): 945-948. DOI: 10.3969/j.issn.1003-8914. 2023.05.044.

82.姚利锋, 段金龙, 王建平, 等. 加味黄连解毒汤联合西药治疗幽门螺杆菌感染性胃溃疡临床研究[J]. 新中医, 2021, 53(6): 21-24. [Yao LF, Duan JL, Wang JP, et al. Clinical study of supplemented Huanglian Jiedu decoction combined with Western medicine in the treatment of Helicobacter pylori infected gastric ulcer[J]. Journal of new Chinese Medicine, 2021, 53(6): 21-24.] DOI: 10.13457/j.cnki.jncm.2021.06.005.

83.冯玲倚, 张薇. 香砂六君子汤联合西药治疗幽门螺杆菌相关性消化性溃疡病Meta分析[J]. 中国民间疗法, 2023, 31(7): 72-76, 79, 125. [Feng LY, Zhang W. Meta-analysis of Xiangsha Liujunzi decoction combined with western medicine in the treatment of Helicobacter pylori associated peptic ulcer disease[J]. China's Naturopathy, 2023, 31(7): 72-76, 79, 125.] DOI: 10.19621/j.cnki. 11-3555/r.2023.0724.

84.吴佳栩, 江锋, 匡子禹, 等. 左金丸加味联合西药治疗幽门螺杆菌感染的Meta分析[J]. 湖北中医药大学学报, 2020, 22(6): 122-126. [Wu JX, Jiang F, Kuang ZY, et al. Meta-analysis of Zuojin pill combined with western medicine in the treatment of Helicobacter pylori infection[J]. Journal of Hubei Vniversity of Chinese Medicine, 2020, 22(6): 122-126.] DOI: 10.3969/j.issn.1008-987x.2020.06.34.

85.邱新文. 参芪健胃颗粒联合四联疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎患者的临床效果[J]. 医疗装备, 2021, 34(10): 73-74. [Qiu XW. Clinical effect of Shenqijianwei granules combined with quadruple therapy on chronic atrophic gastritis with Helicobacter pylori positive[J]. Medical Equipment, 2021, 34(10): 73-74.] DOI: 10.3969/j.issn.1002-2376.2021.10.039.